NEW YORK (TheStreet) — U.S. #stockmarkets plummeted on volatile trading Thursday as mixed earnings reports, concerns about the health of the European economy and financial sector and the wait for Friday’s big nonfarm payrolls report rocked the global markets.
Amid the commotion, the bio-therapeutic drugs group was sparkling as #Amarin flew 13.21%. The late-stage biopharmaceutical firm garnered a bullish report from TheStreet’s Adam Feuerstein, who says that Amarin is expected to hear soon on an appeal to a top official at the FDA requesting a reversal of the agency’s revocation of the Special Protocol Assessment (SPA) covering the phase III “ANCHOR” study of its prescription fish-oil pill Vascepa.
All the benchmark indices were down more than 1%, with the #DowJonesIndustrialAverage sinking 1.88% to 16,563.30, the S&P 500 tumbling 2% to 1,930.67, and the #Nasdaq surrendering 2.09% to 4,369.77. The VIX “fear gauge” was spiking more than 27% to 16.98. (at The New York Stock Exchange, Wall Street)